All fields are required.

Close Appointment form

Scientific Advisory Board Test

Improving patient outcomes with innovative drug therapies.

  • Home
  • Scientific Advisory Board Test

Dr. Anatole Besarab

Dr. Anatole Besarab is currently self-employed. He has served as the Chair and Co-Chair of the NKF Workgroup on Vascular Access. He has also served on various committees for the FORUM of ESRD networks, the ASN, NKF, ASAIO, and the NIH. He is author of more than 215 peer reviewed papers, 28 chapters, and 17 monographs. He has presented at and taught at most of the major Nephrology society annual meetings and has been invited to lecture at many academic centers.

Dr. Besarab’s work continues to focus on optimizing the management of anemia focusing on the proper balance between degree of erythropoiesis and iron delivery. In addition, he continues to be a proponent of detecting vascular access dysfunction prior to thrombosis.

Judith D. Bentkover, PhD

Judith D. Bentkover is Professor of the Practice in Health Services Policy and Practice at Brown University’s School of Public Health, Professor of the Practice in the Economics and Community Health Departments at Tufts University. In addition, she is President of Judith Bentkover and Associates, a consulting firm providing assistance to all stakeholders in the healthcare services and health education sectors. She is also former member of the faculty at Harvard University, President and CEO of Innovative Health Solutions, a consulting firm providing research and strategic analysis to healthcare manufacturers, providers, and payers and former Partner-in-Charge of KPMG’s Strategic Health Solutions practice, a global consulting team providing pricing, reimbursement, marketing, and commercialization strategy development. Dr. Bentkover leads international multidisciplinary teams in strategic projects associated with therapy economics. She focuses on applied economic and decision analysis associated with the use of medical products and procedures, establishing reliable estimates of value and cost-effectiveness. Her work includes healthcare policy simulation modeling, scenario analysis, data analysis, forecasting, and meta-analysis. Her work is used as the basis of strategic plans, implementation plans, pricing and reimbursement decisions as well as investment, R &D decisions, and marketing materials.

Dr. Gary M. Brittenham, M.D.

James A. Wolff Professor of Pediatrics and Professor of Medicine, Columbia University, New York, NY, USA

Dr. Gary M. Brittenham, M.D. is involved in basic and clinical research in iron metabolism and disorders of the red blood cell. His interests include the diagnosis, prevention and treatment of both iron deficiency and iron overload, and the evaluation of iron supplements and iron-chelating agents. His studies have examined acquired and inherited forms of anemia, including thalassemia, sickle cell disorders and other hemoglobinopathies, and the pathogenesis of malarial anemia. He has published more than 230 peer-reviewed journal articles and book chapters in these areas. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. Dr. Brittenham has received awards from the U.S. Public Health Service Award for Exceptional Achievement in Orphan Products Development and from the International Association for the Study of Disorders of Iron Metabolism for Contributions to the Understanding of Disorders of Iron Metabolism and has been a Visiting Professor at universities in the U.S., Europe and Asia. At Columbia University, he has served as Director of the Division of Pediatric Hematology, Department of Pediatrics, and is Executive Director of the St. Giles Comprehensive Sickle Cell – Thalassemia Program. Dr. Brittenham received a B.A. degree with honors from John Hopkins University and a M.D. degree from Case Western Reserve University.

Dr. Felix Dahm

Partner and Co-Founder, E3 Life AG, Zug, Switzerland

Dr Felix Dahm is a medical doctor and healthcare executive with extensive senior management experience at private equity-owned healthcare companies. He has provided leadership in corporate strategy, BD, R&D, medical and regulatory affairs and has deep knowledge across the value chain and lifecycle. Felix has outstanding experience in healthcare M&A. He originally trained as an abdominal and transplant surgeon, before joining Boston Consulting Group. He was then part of the leadership teams at Nycomed (Switzerland), Gambro (Sweden) and BSN medical (Germany). He is now a co-founder and partner at E3 Life, a boutique investment firm based in Switzerland.

Dr. Marcos Rothstein

Professor of Medicine in the Nephrology Division at Washington University School of Medicine in St. Louis and Medical Director of Dialysis Services.

Dr. Rothstein received his medical degree from Zulia University in Maracaibo, Venezuela. After relocating to the United States, he completed his internship and residency at Prince George’s Hospital in Cheverly, MD, followed by a Nephrology fellowship at Washington University School of Medicine.

Dr. Rothstein’s clinical interests include all forms of kidney disease and renal replacement therapies. His particular research interest has centered in the identification and treatment of anemia of chronic kidney disease, including iron replacement therapies. Dr. Rothstein has had many publications in high impact journals and has contributed articles to many books, as well as scientific reports. He is a member of the American Federation for Clinical Research, the American Society of Nephrology, the National Kidney Foundation, and the International Society of Nephrology (ISN).

As part of his education and research mission, Dr. Rothstein has led a long-term project in Guatemala, sponsored by the ISN. The goal is to improve Nephrology services in the country.

Dr. Jay Wish

Professor of Clinical Medicine at Indiana University School of Medicine in Indianapolis and Chief Medical Officer for Dialysis at Indiana University Health.

Jay B. Wish, MD, is currently medical director at dialysis facilities in Indianapolis and Muncie, IN. He is past president of the National Forum of ESRD Networks and has been an advisor to the Centers for Medicare and Medicaid Services (CMS) on quality improvement issues in dialysis. He served on the Board of Directors of the Renal Physicians Association and the American Association of Kidney Patients and was the recipient of the latter’s Visionary Award in 2005. Dr. Wish is Vice Chairman of the Editorial Advisory Board for Nephrology News & Issues and on the editorial boards of the Journal of the American Society of Nephrology and Clinical Journal of the American Society of Nephrology. He has had over 100 articles, reviews, and book chapters published, particularly in the areas of ESRD quality oversight/improvement, accountability, anemia management and vascular access.

Giovanni FM Strippoli, MD, PhD

Professor of Nephrology, University of Bari, Italy and Adj. Professor of Epidemiology, University of Sydney, Australia

Giovanni Strippoli is a medical executive with senior experience in medical operations, scientific and medical affairs, research & development and education. Giovanni is a medical graduate and nephrology specialist from the University of Bari, Italy. He holds a Master of Epidemiology and health services regulatory matters at the University of Rome-Tor Vergata (Italy) and a Master of Clinical Epidemiology and PhD at the University of Sydney, Australia. Giovanni serves as the Chairman of the Clinical Research Committee of the International Society of Nephrology (ISN). He has served as council member of the Italian Society of Nephrology and member of the Kidney Disease Improving Global Outcomes (KDIGO) anemia workgroup and Guest Editor of the Caring for Australians with Renal Impairment (CARI) guidelines. He serves in the steering committee of numerous scientific trials internationally and is currently an invited editor for Wyley’s 2nd edition of the Evidence Based Nephrology textbook. Giovanni has senior industry experience in the hemodialysis service business.